Pharmacokinetics, biodistribution, and in vivo toxicity of 7-nitroindazole loaded in pegylated and non-pegylated nanoemulsions in rats

Angela Patricia França,Thais Alves Silva,Daniela Schulz,Leonardo Gomes-Pereira,Livia Melo Arruda Cunha,Merita Pereira Gonçalves,João Victor Soares Vieira,Mariele Paludetto Sanches,Natalia Koehler,Sharbel Maluf,Anicleto Poli,José Eduardo da Silva-Santos,Jamil Assreuy,Elenara Lemos-Senna
DOI: https://doi.org/10.1016/j.ejps.2024.106695
IF: 5.112
2024-01-08
European Journal of Pharmaceutical Sciences
Abstract:Sepsis is a life-threatening condition caused by a dysregulated host response to infection. The development of sepsis is associated with excessive nitric oxide (NO) production, which plays an important role in controlling vascular homeostasis. 7-nitroindazole (7-NI) is a selective inhibitor of neuronal nitric oxide synthase (NOS-1) with potential application for treating NO imbalance conditions. However, 7-NI exhibits a low aqueous solubility and a short plasma half-life. To circumvent these biopharmaceutical limitations, pegylated (NEPEG 7NI ) and non-pegylated nanoemulsions (NENPEG7 NI ) containing 7-NI were developed. This study evaluates the pharmacokinetic profiles and toxicological properties of 7-NI loaded into the nanoemulsions. After a single intravenous administration of the free drug and the nanoemulsions at a dose of 10 mg.kg −1 in Wistar rats, 7-NI was widely distributed in the organs. The pharmacokinetic parameters of C max , t 1/2 , and AUC 0-t were significantly increased after administration of the NEPEG 7NI , compared to both free 7-NI and NENPEG 7NI (p < 0.05). No observable adverse effects were observed after administering the free 7-NI, NEPEG 7NI , or NENPEG 7NI in the animals after a single dose of up to 3.0 mg.kg −1 . The results indicated that 7-NI-loaded nanoemulsions are safe, constituting a promising approach to treating sepsis.
pharmacology & pharmacy
What problem does this paper attempt to address?